Compare CDRE & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRE | TNDM |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | 2013 |
| Metric | CDRE | TNDM |
|---|---|---|
| Price | $30.95 | $17.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $39.67 | $28.00 |
| AVG Volume (30 Days) | 308.9K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ 13.33 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $610,308,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $23.72 | $8.11 |
| Revenue Next Year | $6.89 | $11.85 |
| P/E Ratio | $609.40 | ★ N/A |
| Revenue Growth | 7.53 | ★ 7.93 |
| 52 Week Low | $25.73 | $10.00 |
| 52 Week High | $48.76 | $29.65 |
| Indicator | CDRE | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 55.21 |
| Support Level | $28.89 | $14.44 |
| Resistance Level | $30.96 | $20.79 |
| Average True Range (ATR) | 1.25 | 0.97 |
| MACD | 0.24 | 0.21 |
| Stochastic Oscillator | 76.86 | 68.67 |
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments - the Product segment, which is comprised of components that manufacture and sell products, and the Distribution segment, which is comprised of business that serves as a one-stop shop for law enforcement agencies that sells goods produced by the Product segment, as well as other third-party products.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.